


114

FIG. 1



2/14

FIG.2(A)

MOLT 4





FIG.2(B)

JURKAT



3/14

FIG. 2(C)

K562





FIG. 2(D)

EBV-B



4/14

FIG. 2(E)





FIG. 2(F)



5/14

FIG. 2(G)

ADENOCARCINOMA





FIG. 2(H)

HUH 7



6/14

FIG. 3(A)

PURIFIED RA





FIG. 3(B)

PURIFIED RO



SUBSTITUTE SHEET (RULE 26)

7/14

FIG. 3(C)

CORD BLOOD PURIF. RA





FIG. 3(D)

CORD BLOOD RA PHA STIM.



SUBSTITUTE SHEET (RULE 26)

8/14

FIG. 3(E)





FIG. 3(F)



SUBSTITUTE SHEET (RULE 26)

9/14

E2 CHO (CONF.)




FIG. 4

E2 CHO (CONF.)




FIG. 5

10/14

FIG. 6





FIG. 7



1114

FIG. 8





FIG. 9



12/14

FIG. 10





FIG. 11



13/14

FIG. 12



14/14

FIG. 13

